Immunotherapy for cervical cancer: Can it do another lung cancer?

Cervical cancer, although preventable, is still the second most common cancer among women worldwide. In developing countries like India, where screening for cervical cancer is virtually absent, most women seek treatment only at advanced stages of the disease. Although standard treatment is curative in more than 90% of women during the early stages, for stage IIIb and above this rate drops to 50% or less. Hence, novel therapeutic adjuvants are required to improve survival at advanced stages. Lung cancer has shown the way forward with the use of Immunotherapeutic interventions as standard line of treatment in advanced stages.

Source: Current Problems in Cancer - January 6, 2018 Category: Cancer & Oncology Authors: Priya Ramanathan, Hemavathi Dhandapani, Hascitha Jayakumar, Abirami Seetharaman, Rajkumar Thangarajan Source Type: research